BioAtla (BCAB) Expected to Announce Earnings on Thursday

BioAtla (NASDAQ:BCAB) will likely be posting its quarterly earnings results after the market closes on Thursday, March 27th. Analysts expect BioAtla to post earnings of ($0.40) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

BioAtla Stock Down 0.8 %

Shares of NASDAQ:BCAB opened at $0.37 on Wednesday. BioAtla has a 52 week low of $0.24 and a 52 week high of $4.02. The company has a 50-day moving average price of $0.41 and a 200 day moving average price of $1.15. The company has a market cap of $17.74 million, a P/E ratio of -0.22 and a beta of 1.19.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.